AXSM
Axsome Therapeutics, Inc.$183.37-4.03 (-2.15%)Prev Close$187.40·MCap$9.54B·P/E—·Vol448.6K·Yield—
▲
Buys (12M)
1
$200.5K
▼
Sells (12M)
24
$129.77M
◆
Net Activity
Net Seller
$129.57M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Axsome Therapeutics, Inc. (AXSM) has been dominated by selling, with 1 insider purchase totaling $200.5K and 24 insider sales totaling $129.77M. The most recent insider transaction was by Maizel Ari (officer: Chief Commercial Officer), who sold $1.37M worth of shares on Apr 23, 2026. Axsome Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $9.54B.
AXSM Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Maizel Ari | officer: Chief Commercial Officer | Sell | 7,500 | $182.42 | $1.37M | 0Exit |
| Feb 27, 2026 | Coleman Mark | director | Sell | 25,000 | $161.11 | $4.03M | 47,140-35% |
| Feb 27, 2026 | Jacobson Mark L. | officer: Chief Operating Officer | Sell | 35,378 | $161.88 | $5.73M | 0Exit |
| Feb 2, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 32,410 | $185.60 | $6.02M | 0 |
| Jan 22, 2026 | Pizzie Nick | Chief Financial Officer | Sell | 12,000 | $187.92 | $2.26M | 0 |
| Jan 21, 2026 | Maizel Ari | Chief Commercial Officer | Sell | 7,500 | $184.44 | $1.38M | 0 |
| Jan 5, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 139,414 | $171.30 | $23.88M | 0 |
| Dec 31, 2025 | Saad Mark E | Director | Sell | 37,577 | $165.18 | $6.21M | 0 |
| Dec 2, 2025 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 79,973 | $145.66 | $11.65M | 0 |
| Nov 3, 2025 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 163,939 | $133.07 | $21.82M | 0 |
| Oct 6, 2025 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 45,384 | $119.38 | $5.42M | 0 |
| Sep 22, 2025 | Jacobson Mark L. | Chief Operating Officer | Sell | 10,000 | $115.96 | $1.16M | 0 |
| Sep 16, 2025 | Jacobson Mark L. | Chief Operating Officer | Sell | 45,783 | $114.48 | $5.24M | 0 |
| Sep 12, 2025 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 62,880 | $117.08 | $7.36M | 0 |
| Sep 8, 2025 | Coleman Mark | Director | Buy | 1,575 | $127.28 | $200.5K | 0 |
| Sep 5, 2025 | Saad Mark E | Director | Sell | 9,127 | $125.07 | $1.14M | 0 |
| Sep 2, 2025 | JEFFS ROGER | Director | Sell | 13,464 | $123.68 | $1.67M | 0 |
| Aug 27, 2025 | JEFFS ROGER | Director | Sell | 60,000 | $121.72 | $7.30M | 0 |
| Aug 22, 2025 | JEFFS ROGER | Director | Sell | 36,694 | $120.05 | $4.41M | 0 |
| Jun 20, 2025 | Murdock Hunter R. | General Counsel | Sell | 13,514 | $101.42 | $1.37M | 0 |
| Jun 16, 2025 | Murdock Hunter R. | General Counsel | Sell | 22,500 | $101.19 | $2.28M | 0 |
| Jun 9, 2025 | Jacobson Mark L. | Chief Operating Officer | Sell | 25,000 | $110.44 | $2.76M | 0 |
| May 27, 2025 | Coleman Mark | Director | Sell | 7,500 | $104.45 | $783.4K | 0 |
| May 27, 2025 | Jacobson Mark L. | Chief Operating Officer | Sell | 40,673 | $104.07 | $4.23M | 0 |
| May 20, 2025 | Coleman Mark | Director | Sell | 3,000 | $107.49 | $322.5K | 0 |
| Feb 13, 2025 | Pizzie Nick | Chief Financial Officer | Sell | 15,000 | $130.10 | $1.95M | 0 |
| Aug 9, 2024 | Jacobson Mark L. | Chief Operating Officer | Sell | 47,739 | $84.26 | $4.02M | 0 |
| May 29, 2024 | Jacobson Mark L. | Chief Operating Officer | Sell | 7,910 | $74.31 | $587.8K | 0 |
| May 28, 2024 | Coleman Mark | Director | Sell | 10,497 | $75.17 | $789.1K | 0 |
| Apr 1, 2024 | Jacobson Mark L. | Chief Operating Officer | Sell | 24,662 | $77.24 | $1.90M | 0 |
| Mar 14, 2024 | JEFFS ROGER | Director | Sell | 32,323 | $69.84 | $2.26M | 0 |
| Sep 15, 2023 | Coleman Mark | Director | Sell | 29,588 | $75.18 | $2.22M | 0 |
| Nov 19, 2021 | JEFFS ROGER | Director | Buy | 3,950 | $37.30 | $147.3K | 0 |
| Nov 18, 2021 | Coleman Mark | Director | Buy | 1,430 | $35.09 | $50.2K | 0 |
| Nov 18, 2021 | Pizzie Nick | CHIEF FINANCIAL OFFICER | Buy | 955 | $35.26 | $33.7K | 0 |
| Nov 17, 2021 | Saad Mark E | Director | Buy | 3,200 | $34.53 | $110.5K | 0 |
| May 12, 2021 | Coleman Mark | Director | Buy | 500 | $58.15 | $29.1K | 0 |
AXSM Insider Buying Activity
The following table shows recent insider purchases of Axsome Therapeutics, Inc. (AXSM) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 8, 2025 | Coleman Mark | Director | Buy | 1,575 | $127.28 | $200.5K | 0 |
| Nov 19, 2021 | JEFFS ROGER | Director | Buy | 3,950 | $37.30 | $147.3K | 0 |
| Nov 18, 2021 | Coleman Mark | Director | Buy | 1,430 | $35.09 | $50.2K | 0 |
| Nov 18, 2021 | Pizzie Nick | CHIEF FINANCIAL OFFICER | Buy | 955 | $35.26 | $33.7K | 0 |
| Nov 17, 2021 | Saad Mark E | Director | Buy | 3,200 | $34.53 | $110.5K | 0 |
| May 12, 2021 | Coleman Mark | Director | Buy | 500 | $58.15 | $29.1K | 0 |
AXSM Insider Selling Activity
The following table shows recent insider sales of Axsome Therapeutics, Inc. (AXSM) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Maizel Ari | officer: Chief Commercial Officer | Sell | 7,500 | $182.42 | $1.37M | 0Exit |
| Feb 27, 2026 | Coleman Mark | director | Sell | 25,000 | $161.11 | $4.03M | 47,140-35% |
| Feb 27, 2026 | Jacobson Mark L. | officer: Chief Operating Officer | Sell | 35,378 | $161.88 | $5.73M | 0Exit |
| Feb 2, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 32,410 | $185.60 | $6.02M | 0 |
| Jan 22, 2026 | Pizzie Nick | Chief Financial Officer | Sell | 12,000 | $187.92 | $2.26M | 0 |
| Jan 21, 2026 | Maizel Ari | Chief Commercial Officer | Sell | 7,500 | $184.44 | $1.38M | 0 |
| Jan 5, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 139,414 | $171.30 | $23.88M | 0 |
| Dec 31, 2025 | Saad Mark E | Director | Sell | 37,577 | $165.18 | $6.21M | 0 |
| Dec 2, 2025 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 79,973 | $145.66 | $11.65M | 0 |
| Nov 3, 2025 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 163,939 | $133.07 | $21.82M | 0 |
| Oct 6, 2025 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 45,384 | $119.38 | $5.42M | 0 |
| Sep 22, 2025 | Jacobson Mark L. | Chief Operating Officer | Sell | 10,000 | $115.96 | $1.16M | 0 |
| Sep 16, 2025 | Jacobson Mark L. | Chief Operating Officer | Sell | 45,783 | $114.48 | $5.24M | 0 |
| Sep 12, 2025 | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 62,880 | $117.08 | $7.36M | 0 |
| Sep 5, 2025 | Saad Mark E | Director | Sell | 9,127 | $125.07 | $1.14M | 0 |
| Sep 2, 2025 | JEFFS ROGER | Director | Sell | 13,464 | $123.68 | $1.67M | 0 |
| Aug 27, 2025 | JEFFS ROGER | Director | Sell | 60,000 | $121.72 | $7.30M | 0 |
| Aug 22, 2025 | JEFFS ROGER | Director | Sell | 36,694 | $120.05 | $4.41M | 0 |
| Jun 20, 2025 | Murdock Hunter R. | General Counsel | Sell | 13,514 | $101.42 | $1.37M | 0 |
| Jun 16, 2025 | Murdock Hunter R. | General Counsel | Sell | 22,500 | $101.19 | $2.28M | 0 |
| Jun 9, 2025 | Jacobson Mark L. | Chief Operating Officer | Sell | 25,000 | $110.44 | $2.76M | 0 |
| May 27, 2025 | Coleman Mark | Director | Sell | 7,500 | $104.45 | $783.4K | 0 |
| May 27, 2025 | Jacobson Mark L. | Chief Operating Officer | Sell | 40,673 | $104.07 | $4.23M | 0 |
| May 20, 2025 | Coleman Mark | Director | Sell | 3,000 | $107.49 | $322.5K | 0 |
| Feb 13, 2025 | Pizzie Nick | Chief Financial Officer | Sell | 15,000 | $130.10 | $1.95M | 0 |
| Aug 9, 2024 | Jacobson Mark L. | Chief Operating Officer | Sell | 47,739 | $84.26 | $4.02M | 0 |
| May 29, 2024 | Jacobson Mark L. | Chief Operating Officer | Sell | 7,910 | $74.31 | $587.8K | 0 |
| May 28, 2024 | Coleman Mark | Director | Sell | 10,497 | $75.17 | $789.1K | 0 |
| Apr 1, 2024 | Jacobson Mark L. | Chief Operating Officer | Sell | 24,662 | $77.24 | $1.90M | 0 |
| Mar 14, 2024 | JEFFS ROGER | Director | Sell | 32,323 | $69.84 | $2.26M | 0 |
| Sep 15, 2023 | Coleman Mark | Director | Sell | 29,588 | $75.18 | $2.22M | 0 |
AXSM Insiders
Similar Stocks to AXSM
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B